NLRP3 and gout: Because NLRP3 inflammasome activation has been implicated in the development of several diseases such as gout, asbestosis, metabolic syndrome, and atherosclerosis [50], compound 2 may have a beneficial application for NLRP3 inflammasome-associated diseases based on its inhibitory effect of NLRP3 inflammasome activation in this study.